[en] T cell triggering can be achieved by monoclonal antibodies (mAbs) specific for the CD3/TcR complex. In the presence of appropriate costimulation and/or progression factors, such triggering permits the generation of effector cells for immunotherapy protocols involving the redirection of T cell lysis against tumor cells by mAbs bispecific for anti-CD3/anti-tumor cells (bs-mAbs). Focusing our analysis on the clinically relevant bs-mAb OC/TR, we found that bs-mAbs generated with the same anti tumor specificity, but two other anti-CD3 mAbs, TR66 and OKT3, have the same and a significantly lower lytic potential, respectively, compared with that of OC/TR. To evaluate the relevance of the anti-CD3 component, we examined several anti-CD3 mAbs with respect to binding parameters and the ability to trigger T lymphocytes. Competitive binding assays suggested that all anti-CD3 mAbs recognized the same or overlapping epitopes, although mAbs BMA030 and OC/TR bound with lower avidity than did alpha CD3 (the bivalent anti-CD3 mAb produced by the hybrid hybridoma OC/TR). TR66 and OKT3, as determined by measurement of the affinity constants. In all lymphocyte populations examined, which included resting peripheral blood mononuclear cells (PBMC), activated PBMC and T cell clones, OKT3, BMA033 and OC/TR failed to mobilize Ca2+ without cross-linking, whereas alpha CD3, in both murine and murine-human chimeric versions, TR66 and BMA030, did not require cross-linking. The ability to induce CD3 modulation was associated in part with the induction of Ca2+ fluxes. Despite the differences in the behavior of these mAbs in triggering the events that precede proliferation, all of them ultimately led to expression of the IL-2 receptor and to proliferation in T cells in the presence of accessory cells. Our data suggest that anti-CD3 mAbs that bind more rapidly (strong Ca2+ mobilizers) and more tightly under physiological conditions are good candidates for retargeting T cells in the bs-mAb clinical application.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Jacobs, Nathalie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Mazzoni, A.
Mezzanzanica, D.
Negri, D. R.
Valota, O.
Colnaghi, M. I.
MOUTSCHEN, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
Boniver, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Canevari, Silvana; Fondazione IRCCS Istituto Nazionale dei Tumori > Experimental Oncology Department
Language :
English
Title :
Efficiency of T Cell Triggering by Anti-Cd3 Monoclonal Antibodies (Mab) with Potential Usefulness in Bispecific Mab Generation
Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, Sturm E, Warnaar SO, Bolhuis RLH (1993) Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol 151:2904
Boerman TJG, Massuger OC, Schijf CPT, Claessens RAMJ, Corstens FHM (1996) Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer 66:477
Bolhuis RLH, Van de Griend RJ (1985) PHA induced proliferation and cytolytic activity in T3+, but not in T3- cloned T lymphocytes, requires the involvement of the T3 antigen for signal transmission. Cell Immunol 93:46
Bolhuis RLH, Lamers CHJ, Goey HS, Eggermont AMM, Trimbos JB, Stoter G, Lanzavecchia A, Di Re E, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int J Cancer 7:78
Canevari S, Mezzanzanica D, Mazzoni A, Negri DRM, Ramakrishna V, Bolhuis RLH, Colnaghi MI, Bolis G (1995) Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 4:423
Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463
Davis LS, Wacholtz MC, Lipsky PE (1989) The induction of T cell unresponsiveness by rapidly modulating CD3. J Immunol 142:1084
De Gast GC, Haagen I-A, Van Houten AA, Klein SC, Duits AJ, De Weger RA, Vroom TM, Clark MR, Phillips J, Van Dijk AJG, De Lau WBM, Bast BJEG (1995) CD8 T cell activation after intravenous administration of CD3 CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390
Kroesen BJ, Buter J, Sleijfer DT, Janssen RAJ, Van der Graaf WTA, The TH, de Leij L, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652
Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105
Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE (1986) Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. J Immunol 136:3945
Marchalonis JJ (1969) An enzymatic method for the trace iodination of immunoglobulin and other proteins. Biochem J 113:299
Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI (1988) Human ovarian carcinoma lysis by cytotoxicity T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 41:609
Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR (1991) Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716
Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297
Mueller DL, Jenkins MK, Schwartz, RH (1989) Clonal expansion vs functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445
Oettgen HC, Terhorst C, Cantley LC, Rosoff PM (1985) Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell 40:583
Oi VT, Morrison SL (1986) Chimeric antibodies. Biotechniques 4:214
Ortho Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337
Pichler WJ, Walker C, Bettens F, Koponen M, Von Tscharner V, Kurrle R, Snow C, DeWeck AL (1987) Differences of T cell activation by the anti-CD3 antibodies Leu4 and BMA030. Cell Immunol 108:175
Poenie M, Tsien RY, Schmitt-Verhulst A-M (1987) Sequential activation and lethal hit measured by [Ca2+]i in individual cytolytic T cells and targets. EMBO J 6:2223
Pupa SM, Canevari S, Fontanelli R, Ménard S, Mezzanzanica D, Lanzavecchia A, Colnaghi MI (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int J Cancer 42:455
Pupa SM, Canevari S, Colzani E, Damgard EM, Ménard S, Miotti S, Colnaghi MI (1991) Purification of bispecific monoclonal antibodies produced by a hybrid hybridoma. J Immunol Res 3:16
Rabinovitch PS, June CH, Grossmann A, Ledbetter JA (1986) Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol 137:952
Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179
Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833
Rigley K, Slocombe P, Proudfoot K, Wahid S, Mandair K, Bebbington C (1995) Human p59fyn(T) regulates OKT3-induced calcium influx by a mechanism distinct from PIP2 hydrolysis in Jurkat T cells. J Immunol 154:1136
Roosnek E, Lanzavecchia A (1989) Triggering T cells by otherwise inert hybrid anti-CD3/anti-tumor antibodies requires encounter with the specific target cell. J Exp Med 170:297
Roosnek EE, Van Lier RA, Aarden LA (1987) Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur J Immunol 17:1507
Schwinzer R, Franklin RA, Domenico J, Renz H, Gelfand EW (1992) Monoclonal antibodies directed to different epitopes in the CD3-TCR complex induce different states of competence in resting human T cells. J Immunol 148:1322
Segal DM, Urch CE, George AJT, Jost CR (1991) Bispecific antibodies in cancer treatment. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia
Spits H, Yssel H, Leeuwenberg J, De Vries JE (1985) Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol 15:88
Tibben JG, Boerman OC, Claessens RAMJ, Corstens FHM, Van Deuren M, De Mulder PHM, Van der Meer JWM, Keijser KGG, Massuger LFAG (1993) Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab)2. J Natl Cancer Inst 85:1003
Tunnacliffe A, Olsson C, Traunecker A, Krissansen GW, Karjalainen K, De la Hera A (1989) The majority of CD3 epitopes are conferred by the epsilon chain. In: Knapp K, Dörken B, Rieber EP, Stein H, Gilks WR, Schmidt RE, Von dem Borne AEGK (eds) Leucocyte typing, vol IV: White cell differentiation antigens. Oxford University Press, Oxford, p 295
Valitutti S, Dessing M, Aktories K (1995) Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med 181:577
Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148
Vandenberghe PA, Ceuppens JL (1990) Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. J Immunol 127:197
Van Wauwe JP, De Mey JR, Goossens JG (1980) OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 124:2708
Wacholtz MC, Lipslky PE (1993) Anti-CD3-stimulated Ca2+ signal in individual human peripheral T cells. J Immunol 150:5338
Weiner GJ, De Gast GC (1995) Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma 16:199
Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J (1986) The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol 4:593
Zhu Z, Carter P (1995) Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. Immunol 155:1903